Charles River Laboratories International, Inc.: Form 10-Q for the period ended Jul 1, 2023
Filed with the SEC on Aug 9, 2023 and accepted by EDGAR at Aug 9, 2023, 09:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-07-01. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-02 to 2023-07-01 | $1.06bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-07-01 | $2.09bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Selling, general and administrative | 3 months2023-04-02 to 2023-07-01 | $199.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-01-01 to 2023-07-01 | $374.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-02 to 2023-07-01 | $164.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-07-01 | $332.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-02 to 2023-07-01 | $35.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-07-01 | $69.4m | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-02 to 2023-07-01 | $29.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-07-01 | $56.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-02 to 2023-07-01 | $97.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-07-01 | $200.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-02 to 2023-07-01 | $1.89 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-07-01 | $3.90 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-02 to 2023-07-01 | $1.89 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-07-01 | $3.91 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-02 to 2023-07-01 | 51,467,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-07-01 | 51,382,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-07-01 | $257.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-04-02 to 2023-07-01 | $67.4m | us-gaap:PaymentsToAcquireProductiveAssets |
| Capital expenditure | 6 months2023-01-01 to 2023-07-01 | $174.3m | us-gaap:PaymentsToAcquireProductiveAssets |
| Share repurchases | 6 months2023-01-01 to 2023-07-01 | $24.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-07-01 | $200.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-07-01 | $1.50bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-07-01 | $7.77bn | us-gaap:Assets |
| Current liabilities | At period end2023-07-01 | $1.01bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-07-01 | $4.47bn | us-gaap:Liabilities |
| Current portion of debt | At period end2023-07-01 | $1.2m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-07-01 | $3.25bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001100682-23-000018. Last ingested by Listed: Nov 5, 2026, 13:54 ET. Listed shows no prices and gives no investment advice.